Synlogic Appoints Patricia N. Hurter, Ph.D. to Board of Directors

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Synlogic,
Inc.
, (Nasdaq:SYBX) a clinical stage company applying synthetic
biology to beneficial microbes to develop novel, living medicines, today
announced the appointment of Patricia N. Hurter, Ph.D., Senior Vice
President of Pharmaceutical and Preclinical Sciences at Vertex
Pharmaceuticals, Inc., to its board of directors.


“I am delighted to welcome Trish to our Board,” said Aoife Brennan,
M.B., Ch.B., Synlogic’s president and chief executive officer. “She has
been a key member of the leadership team that took Vertex from its early
stages to one of the most admired biopharma companies, with the approval
of several breakthrough drugs. Her broad experience in drug discovery
and development, global regulatory affairs and GMP manufacturing will be
invaluable to Synlogic as we develop Synthetic Biotic medicines that
have the potential to change patients’ lives.”

“Synlogic has established itself as a leader in the application of
synthetic biology to the creation of a new class of living medicines,”
stated Dr. Hurter. “I am excited to have the opportunity to work closely
with the company’s management to help them develop Synlogic’s novel
platform, which has broad potential application across therapeutic areas
from metabolic disease to cancer, and to bring these novel medicines to
the patients who need them.”

Dr. Hurter has been Senior Vice President at Vertex since 2011, during
which time her responsibilities grew to include all CMC and preclinical
development activities of Vertex’s R&D portfolio , as well as the
internal GMP manufacturing facility that provides drug substance and
product for clinical development and commercial supply. From 2013 to
2014, she served as Interim Head of Global Regulatory Affairs at Vertex
and oversaw the submission of the new drug application for Orkambi®,
as well as several label expansions for Kalydeco®. She has
played a leadership role in the development and commercialization of 4
transformative therapies for Vertex: Incivek®, Kalydeco,
Orkambi® and Symdeko®. Prior to joining Vertex,
Dr. Hurter was Director, Formulation Design and Characterization for
Merck where she was a key member of the early development team for
Januvia®, a treatment for Type II diabetes.

A respected thought leader in the pharmaceutical industry, Dr. Hurter is
a frequent contributor to many scientific publications. She serves on
the Vertex Research & Development and Operating Committees and is the
founder and executive sponsor of “IWILL,” a Vertex employee network
devoted to the advancement of women leaders. Dr. Hurter also serves as a
member of the Board of Trustees of Harvard Conservation Trust. She holds
a Ph.D. in chemical engineering from the Massachusetts Institute of
Technology, an M.S. in mechanical engineering from West Virginia
University and earned a B.Sc. in chemical engineering, cum laude,
from the University of KwaZulu-Natal in Durban, South Africa.

About Synlogic
Synlogic is pioneering the development of a
novel class of living medicines, Synthetic Biotic medicines, based on
its proprietary drug development platform. Synlogic leverages the tools
and principles of synthetic biology to genetically engineer beneficial
microbes to perform or deliver critical functions missing or damaged due
to disease. Synthetic Biotic medicines are designed to act locally and
have a systemic effect to address disease in patients. Synlogic’s two
lead programs, SYNB1020 and SYNB1618, are orally administered and target
hyperammonemia as a result of liver damage or genetic disease, and
phenylketonuria, respectively. Synlogic is also developing SYNB1891 as
an intratumorally-administered Synthetic Biotic medicine for the
treatment of cancer. In addition, the company is leveraging the broad
potential of its platform to create additional Synthetic Biotic
medicines for the treatment of liver disease, as well as inflammatory
and immune disorders including Synlogic’s collaboration with AbbVie to
develop Synthetic Biotic-based treatments for inflammatory bowel disease
(IBD). For more information, please visit www.synlogictx.com.

Forward-Looking Statements
This press release contains
“forward-looking statements” that involve substantial risks and
uncertainties for purposes of the safe harbor provided by the Private
Securities Litigation Reform Act of 1995. All statements, other than
statements of historical facts, included in this press release regarding
strategy, future operations, future financial position, future revenue,
projected expenses, prospects, plans and objectives of management are
forward-looking statements. In addition, when or if used in this press
release, the words “may,” “could,” “should,” “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “plan,” “predict” and similar
expressions and their variants, as they relate to Synlogic may identify
forward-looking statements. Examples of forward-looking statements,
include, but are not limited to, statements regarding the potential of
Synlogic’s platform to develop therapeutics to address a wide range of
diseases, including: cancer, rare metabolic diseases, liver disease, and
inflammatory and immune disorders; the future clinical development of
Synthetic Biotic medicines; the approach Synlogic is taking to discover
and develop novel therapeutics using synthetic biology; the potential of
Synlogic’s technology to treat cancer, hyperammonemia, and
phenylketonuria. Actual results could differ materially from those
contained in any forward-looking statement as a result of various
factors, including: the uncertainties inherent in the preclinical
development process; the ability of Synlogic to protect its intellectual
property rights; and legislative, regulatory, political and economic
developments, as well as those risks identified under the heading “Risk
Factors” in Synlogic’s filings with the SEC. The forward-looking
statements contained in this press release reflect Synlogic’s current
views with respect to future events. Synlogic anticipates that
subsequent events and developments will cause its views to change.
However, while Synlogic may elect to update these forward-looking
statements in the future, Synlogic specifically disclaims any obligation
to do so. These forward-looking statements should not be relied upon as
representing Synlogic’s view as of any date subsequent to the date
hereof.

Orkambi® and Kalydeco®
are registered trademarks of Vertex Pharmaceuticals, Inc. Januvia
®
is a registered trademark of Merck & Co.

Contacts

MEDIA:
Courtney Heath
Phone: 617-872-2462
Email: [email protected]

INVESTORS:
Elizabeth Wolffe, Ph.D.
Phone: 617-207-5509
Email:
[email protected]

error: Content is protected !!